Dr. Daniel (Yingxu) Peng works in the Science Staff at the Office of Generic Drugs (OGD). Prior to joining OGD, Dr. Peng was a Senior Formulation Scientist in Pharmaceutical Development department of AstraZeneca for 4 years. Dr. Peng obtained his Ph.D. in Pharmaceutics from West China University of Medical Sciences in 1998 and worked as Assistant Professor in Shanghai Institute of Pharmaceutical Industry for 2 years. He completed post-doctoral research at College of Pharmacy, University of Tennessee Health Science Center (UTHSC). He then served as faculty in UTHSC for 4 years. He has published 3 book chapters, 16 peer reviewed papers and 4 US patent applications. Dr. Peng has extensive experience in formulation and process development for solid dosage forms. He is also skilled in applying DOE, MVA and ANN software for pharmaceutical product development. Currently, he is a member of OGD IR/MR working group on Quality by Design (QbD).